| 214.68 0.934 (0.44%) | 01-09 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 257.11 | 1-year : | 300.3 |
| Resists | First : | 220.13 | Second : | 257.11 |
| Pivot price | 212.33 |
|||
| Supports | First : | 210.79 | Second : | 205.02 |
| MAs | MA(5) : | 214.01 |
MA(20) : | 211.38 |
| MA(100) : | 193.37 |
MA(250) : | 176.98 |
|
| MACD | MACD : | 2 |
Signal : | 2 |
| %K %D | K(14,3) : | 71.7  |
D(3) : | 73.6 |
| RSI | RSI(14): 56.9 |
|||
| 52-week | High : | 220.13 | Low : | 141.38 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FBT ] has closed below upper band by 34.1%. Bollinger Bands are 10.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 216.17 - 217.03 | 217.03 - 217.77 |
| Low: | 211.61 - 212.68 | 212.68 - 213.6 |
| Close: | 212.85 - 214.58 | 214.58 - 216.07 |
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Fri, 09 Jan 2026
Biotech Could Be One of 2026’s Biggest Winners, and This ETF Is Perfectly Positioned - 24/7 Wall St.
Thu, 01 Jan 2026
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
Wed, 31 Dec 2025
Responsive Playbooks and the FBT Inflection - Stock Traders Daily
Thu, 25 Dec 2025
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
Thu, 02 Oct 2025
The Best Biotech ETFs to Buy - Kiplinger
Wed, 01 Oct 2025
Best Biotech ETFs to Watch Right Now - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|